26 Pharmaceuticals Stocks to Sell Now

26 Pharmaceuticals Stocks to Sell Now

The ratings of 26 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Allergan plc (AGN) earns a F this week, moving down from last week’s grade of D. Allergan plc is a healthcare company focused on developing and commercializing pharmaceuticals, biologics, and medical devices. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of AGN stock.

Eli Lilly and Company (LLY) is having a tough week. The company’s rating falls from a C to a D. Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. For more information, get Portfolio Grader’s complete analysis of LLY stock.

Mylan N.V. (MYL) declines this week from a C to a D. Mylan N.V. is a global generic and specialty pharmaceuticals company. For more information, get Portfolio Grader’s complete analysis of MYL stock.

Medicines Company’s (MDCO) rating weakens this week, dropping to a D versus last week’s C. Medicines Company develops products that improve specialized care. The company also gets F’s in sales growth and return on equity. For more information, get Portfolio Grader’s complete analysis of MDCO stock.

This week, Pfizer Inc. (PFE) drops from a C to a D rating. Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. For more information, get Portfolio Grader’s complete analysis of PFE stock.

Slipping from a C to a D rating, Astrazeneca PLC Sponsored ADR (AZN) takes a hit this week. Astrazeneca PLC Sponsored ADR is a biopharmaceutical company focused on therapy related to cardiovascular health, gastrointestinal health, infection, neuroscience, oncology and respiratory health, and inflammation. The company also gets F’s in earnings growth and earnings momentum. For more information, get Portfolio Grader’s complete analysis of AZN stock.

Impax Laboratories, Inc. (IPXL) gets weaker ratings this week as last week’s D drops to a F. Impax Laboratories, Inc. develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The company also gets F’s in sales growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of IPXL stock.

This is a rough week for Horizon Pharma plc (HZNP). The company’s rating falls to D from the previous week’s C. Horizon Pharma plc is a biopharmaceutical company that is developing and commercializing innovative medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company also gets F’s in earnings revisions and earnings momentum. For more information, get Portfolio Grader’s complete analysis of HZNP stock.

Collegium Pharmaceutical, Inc. (COLL) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of COLL stock.

This week, Revance Therapeutics, Inc.’s (RVNC) rating worsens to a F from the company’s D rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of RVNC stock.

Intra-Cellular Therapies, Inc. (ITCI) slips from a D to a F this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ITCI stock.

Intersect ENT Inc (XENT) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of XENT stock.

This week, Zogenix, Inc.’s (ZGNX) rating worsens to a D from the company’s C rating a week ago. Zogenix, Inc. is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZGNX stock.

Teligent, Inc. (TLGT) declines this week from a C to a D. The company also gets F’s in operating margin growth, earnings growth, and return on equity. For more information, get Portfolio Grader’s complete analysis of TLGT stock.

This week, TherapeuticsMD, Inc. (TXMD) drops from a C to a D rating. TherapeuticsMD, Inc. operates as a women’s healthcare product company in the United States. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of TXMD stock.

Cumberland Pharmaceuticals Inc. (CPIX) earns a F this week, moving down from last week’s grade of D. Cumberland Pharmaceuticals Inc. engages in the acquisition, development, and commercialization of branded prescription products for the hospital acute care and gastroenterology markets primarily in the United States. The company also gets F’s in sales growth, operating margin growth, and earnings growth. For more information, get Portfolio Grader’s complete analysis of CPIX stock.

Aradigm Corporation’s (ARDM) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARDM stock.

This is a rough week for Achaogen, Inc. (AKAO). The company’s rating falls to D from the previous week’s C. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AKAO stock.

Slipping from a C to a D rating, Aralez Pharmaceuticals Inc. (ARLZ) takes a hit this week. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ARLZ stock.

Endocyte, Inc. (ECYT) gets weaker ratings this week as last week’s D drops to a F. Endocyte, Inc. is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ECYT stock.

AcelRx Pharmaceuticals, Inc. (ACRX) is having a tough week. The company’s rating falls from a C to a F. AcelRx Pharmaceuticals, Inc. focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company also gets F’s in sales growth, earnings growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACRX stock.

BioDelivery Sciences International, Inc. (BDSI) slips from a D to a F this week. BioDelivery Sciences International, Inc. is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology. The company also gets F’s in earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of BDSI stock.

This is a rough week for Dipexium Pharmaceuticals, Inc. (DPRX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of DPRX stock.

EyeGate Pharmaceuticals, Inc. (EYEG) slips from a C to a D this week. The company also gets F’s in earnings revisions, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of EYEG stock.

This week, Acasti Pharma Inc. Class A (ACST) drops from a C to a D rating. Acasti Pharma Inc. Class A is a pharmaceutical company that develops drugs for cardiovascular diseases. The company also gets F’s in sales growth, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of ACST stock.

VIVUS, Inc. (VVUS) declines this week from a C to a D. VIVUS, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic products for large underserved markets. The company also gets F’s in sales growth and free cash flow. For more information, get Portfolio Grader’s complete analysis of VVUS stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/26-pharmaceuticals-stocks-to-sell-now/.

©2019 InvestorPlace Media, LLC